These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37243243)

  • 41. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
    Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
    J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sildenafil in pediatric pulmonary arterial hypertension.
    Dhariwal AK; Bavdekar SB
    J Postgrad Med; 2015; 61(3):181-92. PubMed ID: 26119438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
    Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
    J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC; Hummel YM; van der Meer P; Berger RM; Damman K; van Veldhuisen DJ; Voors AA; Hoendermis ES
    Eur J Heart Fail; 2017 Jan; 19(1):116-125. PubMed ID: 27873388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis.
    Buendía JA; Patiño DG; Lindarte EF
    Pediatr Pulmonol; 2023 May; 58(5):1562-1568. PubMed ID: 36797849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of inhaled nitrite in addition to sildenafil in thalassemia patients with pulmonary hypertension: A 12-week randomized, double-blind placebo-controlled clinical trial.
    Sasiprapha T; Pussadhamma B; Sibmooh N; Sriwantana T; Pienvichit P; Chuncharunee S; Yingchoncharoen T
    Nitric Oxide; 2022 Mar; 120():38-43. PubMed ID: 35026396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial.
    Pels A; Derks J; Elvan-Taspinar A; van Drongelen J; de Boer M; Duvekot H; van Laar J; van Eyck J; Al-Nasiry S; Sueters M; Post M; Onland W; van Wassenaer-Leemhuis A; Naaktgeboren C; Jakobsen JC; Gluud C; Duijnhoven RG; Lely T; Gordijn S; Ganzevoort W;
    JAMA Netw Open; 2020 Jun; 3(6):e205323. PubMed ID: 32585017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome.
    Mohammed S; Vijayvergiya R; Malhotra S; Rohit MK
    Indian Heart J; 2021; 73(5):633-636. PubMed ID: 34627582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
    Ghofrani HA; Wiedemann R; Rose F; Olschewski H; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    Ann Intern Med; 2002 Apr; 136(7):515-22. PubMed ID: 11926786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sildenafil: a review of its use in pulmonary arterial hypertension.
    Croom KF; Curran MP
    Drugs; 2008; 68(3):383-97. PubMed ID: 18257613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
    Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
    Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
    Ramani GV; Park MH
    Drug Des Devel Ther; 2010 May; 4():61-70. PubMed ID: 20531962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of oral sildenafil therapy on health-related quality of life in adults with pulmonary arterial hypertension related to uncorrected secundum atrial septal defect: a quasi experimental study.
    Hidayati F; Gharini PPR; Hartopo AB; Anggrahini DW; Dinarti LK
    Health Qual Life Outcomes; 2020 Aug; 18(1):278. PubMed ID: 32795300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension.
    Rhee SJ; Shin SH; Oh J; Jung YH; Choi CW; Kim HS; Yu KS
    Sci Rep; 2022 May; 12(1):7393. PubMed ID: 35513541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.
    Palma G; Giordano R; Russolillo V; Cioffi S; Palumbo S; Mucerino M; Poli V; Vosa C
    Tex Heart Inst J; 2011; 38(3):238-42. PubMed ID: 21720460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.